Anticoagulation Management Service Guideline.07242016

Both factor Xa inhibitors have gained FDA approved indications for the prevention of VTE after elective total knee or hip arthroplasty and prevention of stroke or systemic embolism in non-valvular atrial fibrillation. Additionally, rivaroxaban has an FDA labeled indication for VTE treatment (1,3-5). ................
................